COMP <GO>
GVA vs TMO // EV/EBITDA & P/E VALUATION
Granite Construction Incorporated (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: GVA 8
— TMO 6
▲ EV/EBITDA & P/E VALUATION LEADER: GVA
LAST: $123.62 (+1.59%) • MKT CAP: $5.33B
valuation
14.4x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GVA VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GVA | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.10% | 41.00% | -24.90 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 9.30% | +4.50 | GVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 14.4x | 30.4x | -16.00 | GVA | /valuation <GO> |
| Free Cash Flow Yield | 6.21% | 2.40% | +3.81 | GVA | /fcf-yield <GO> |
| Operating Margin | 6.40% | 17.40% | -11.00 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.40% | 15.10% | -10.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 3.90% | +6.50 | GVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.43% | 0.24% | +0.19 | GVA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.35 | 4.50 | -1.15 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.4 | 59.1 | +7.27 | GVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.94 | +0.04 | GVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.7x | 36.3x | -10.60 | GVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.33B | $262.22B | -$256.89B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GVA REV | TMO REV | GVA GROSS % | TMO GROSS % | GVA FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.42B | $44.56B | 16.1% | 44.0% | $330.6M | $6.29B |
| FY 2024 | $4.01B | $42.88B | 14.3% | 44.0% | $319.9M | $7.27B |
| FY 2023 | $3.51B | $42.86B | 44.0% | 44.0% | $25.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GVA // BETA 0.98
TMO // BETA 0.94